A Phase II Study of The Pineal Hormones Melatonin And
5-Methoxytryptamine Plus Cannabidiol in Association
with Angiotensin 1-7 in the Treatment of Advanced Solid
Tumour Patients Eligible for The Only Best Supportive
Care
Volume 6 - Issue 2
Paolo Lissoni, Giorgio Porro, Giusy Messina, Carla Galli, Giuseppe Di Fede, Agnese Valentini1, Ana Cristina Simoese-
Silva2 and Daniel Pedro Cardinali3
- Institute of Biological Institute, Milan, Lombardia, Italy
- 1Madonna del Soccorso Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy
- 2Laboratório Interdisciplinar de Investigação Medica, Faculdade de Medicina, UFMG Belo Horizonte, Brazil
- 3Pontificia Universitad Catolica Argentina, Buenos Aires, Argentina
Received: April 08, 2021 Published: April 20, 2021
Corresponding author: Paolo Lissoni, paolo.lissoni@gmx.com, Italy
DOI: 10.32474/RRHOAJ.2021.06.000234
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
The recent advances in the investigation of tumour biology have demonstrated that the human body may produce several
molecules provided by a natural anticancer activity without any toxicity, in particular the pineal hormones melatonin (MLT),
5-methoxytryptamine (5-MTT) and pinealine, the endogenous cannabinoids, oxytocin, and angiotensin 1-7 (Ang 1-7). Unfortunately,
despite their well confirmed anticancer and non-toxic properties, very few clinical studies have been performed in an attempt to
evaluate the potential therapeutic efficacy of the endogenous human anticancer molecules in the treatment of cancer patients, at
least of those eligible for the only palliative therapy. Moreover, most studies have been generally limited to the use of the only pineal
MLT. The present preliminary study was carried out to evaluate the anticancer efficacy of an oral administration of MLT (100 mg in
the dark period) in association with 5-MTT (10 mg in the light period), the cannabinoid agent cannabidiol (CBD) ( 10 mg twice/day)
and Ang 1-7 (0.5 mg/twice day) in a group of 14 untreatable advanced or metastatic cancer patients. The clinical response consisted
of partial response (PR) in 2/14 (14%), and stable disease (SD) in 8/14 (57%). Then, a disease control (PR + SD) was achieved
in 10/14 (71%), whereas the remaining 4/14 (29%) had a progressive disease. Moreover, disease control was associated with a
significant increase in lymphocyte-to-monocyte ratio (LMR), by showing that the control of the neoplastic growth is mediated at
least in part by an improvement in the antitumor immune status of cancer patients.The treatment was well tolerated in all patients,
and in particular no important decline in blood pressure values occurred. On the contrary, a clear improvement in asthenia was
obtained in 8/10 (80%) patients with important asthenia prior to study. This preliminary study may suggest that after the failure
of the common standard anticancer therapies, the administration of the main endogenous anticancer neuroendocrine molecules,
firstly MLT and Ang 1-7, could constitute an alternative approach to cancer patients instead of the simple best supportive care alone.
Keywords: Angiotensin 1-7; Cannabidiol; Melatonin; Metastatic cancer; 5-Methoxytryptamine; Palliative therapy
Abstract|
Introduction|
Patients and Methods|
Results|
Discussion|